CompletedPhase 2

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

United States288 participantsStarted 2023-10-30

Plain-language summary

The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Previous sinonasal surgery for CRS, including but not limited to fenestrated endoscopic sinus surgery and balloon sinuplasty.
✓. Received medical treatment with systemic corticosteroids (SCS) to treat symptoms of CRS as defined by any dose and duration within 1 year of Screening Visit or intolerance/contraindication to SCS.
✓. Received a course of antibiotics to treat symptoms of CRS within 1 year before the Screening Visit.

What they're measuring

Change From Baseline to the 28-day Average of Daily Sinus Total Symptom Score (sTSS) at Week 24

Timeframe: Baseline and Week 24

Trial details

NCT IDNCT06013241

SponsorInsmed Incorporated

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-09-30

View on ClinicalTrials.gov More Chronic Rhinosinusitis Without Nasal Polyps trials